PTP4A3 and neoplasm: Regardless of the route employed, we propose that the externalization of PRL3 in tumors makes it possible to selectively target this oncoprotein with antibody therapy in the same manner as conventional targeting of classical cell surface or secreted targets, ultimately resulting in feedforward “kill-and-leak” cascades facilitating tumor elimination (Fig. 5d).